Ⓜ️Initially developed as an inhalational anesthetic, but withdrawn due to concerns about nephrotoxicity and hepatotoxicity.
Ⓜ️In view of its analgesic properties it is now used, mainly in Australia and New Zealand, to provide short-term analgesia for painful procedures and in the prehospital setting (Grindlay and Babl, 2009).
Ⓜ️Administration is via a dedicated single-use inhaler dispensing 0.2–0.4% methoxyflurane.
Ⓜ️The limited data on efficacy suggest that methoxyflurane administered as a single dose as described above provides effective analgesia resulting in high patient satisfaction with no evidence of toxicity (Grindlay and Babl, 2009).
Ⓜ️There is no good evidence regarding the safety of repeated doses, for example, for analgesia during daily dressing changes.
Ref:
Acute Pain Management; A Practical Guide, Pamela E. Macintyre , Stephan A. Schug, 4/e
No comments:
Post a Comment